The 2025 Poison-Control Spike Is Real — and It's a 7-OH Story, Not a Leaf Story

Why it matters

Kratom-related poison-control calls more than doubled in 2025 compared to the prior four-year average. Federal data attributes the spike to concentrated semisynthetic 7-OH products entering the market — not a change in natural leaf use.

The big picture

The 2025 spike in poison-control calls related to kratom is real and significant. It is also being routinely cited to justify natural-leaf prohibition — without the product-form context the CDC itself includes in its analysis. The spike tells a specific story, and it's not the one in most headlines.

Key findings

• 2015 baseline: 258 reported exposure calls.
• 2018–2024 average: approximately 1,366 calls/year (stable, no significant growth trend).
• 2025 spike: 3,434 calls — more than double the prior-year average.
• CDC 2026 NPDS analysis: surge coincided with 'high-potency semisynthetic formulations including 7-OH' entering the market.
• CDC caution: NPDS data cannot distinguish natural leaf, semisynthetic products, or concentrated formulations.
• U.S. consumer population grew approximately 53% during 2018–2024; call rates did not grow proportionally during the stable period.
• FDA enforcement in 2025 specifically targeted concentrated 7-OH derivative products — not natural leaf.
• A call to poison control is a report, not a confirmed medical outcome; severity, dose, co-drugs, and product form are not in the call count.

What they say

"The spike is real. The product category is blurred. The denominator matters. Severe outcomes are not single-substance stories." — Open Truth Project, citing CDC 2026 NPDS

Bottom line

A graph that cannot separate natural leaf from concentrated 7-OH cannot honestly justify a leaf ban. The 2025 data points at a product market problem — and federal regulators have already moved against the specific product class responsible.